Stermer E, Tabak M, Potasman I, Levy N, Tamir A, Neeman I
Department of Gastroenterology, Faculty of Medicine, Technion, Haifa, Israel.
J Clin Gastroenterol. 1997 Jul;25(1):323-7. doi: 10.1097/00004836-199707000-00005.
Because Helicobacter pylori is an acid-sensitive organism, an elevation of the gastric pH by H2 inhibitors might improve the intragastric conditions for the development of this organism. We tested this hypothesis in a prospective and controlled trial including 43 patients positive for H. pylori using the rapid urease test. Twenty-six patients received 150 mg ranitidine twice daily and 17 patients received no treatment. The 14C-urea breath test was performed in both groups at the beginning of the study and 2 weeks later. Radioactive 14C in exhaled carbon dioxide was significantly increased (p = 0.045) in the patients treated with ranitidine, compared with the patients in the control group. Administration of this drug to patients infected with H. pylori is associated with an increase in the bacterial load after 2 weeks of treatment. This phenomenon might be attributed to increased bacterial growth due to the H2 blocker.
由于幽门螺杆菌是一种对酸敏感的微生物，H2抑制剂提高胃内pH值可能会改善该微生物生长的胃内环境。我们在一项前瞻性对照试验中对这一假设进行了检验，该试验纳入了43例经快速尿素酶试验检测幽门螺杆菌呈阳性的患者。26例患者每日两次服用150毫克雷尼替丁，17例患者未接受治疗。在研究开始时和2周后，两组均进行了14C尿素呼气试验。与对照组患者相比，接受雷尼替丁治疗的患者呼出二氧化碳中的放射性14C显著增加（p = 0.045）。给感染幽门螺杆菌的患者服用这种药物与治疗2周后细菌载量增加有关。这种现象可能归因于H2阻滞剂导致细菌生长增加。
